FDA tightens oversight of compounded GLP-1 prescriptions as supply stabilizes

FDA is tightening oversight of compounded GLP-1 prescriptions as supply for key medicines such as semaglutide and tirzepatide stabilizes. For many patients, that does not mean access disappears overnight. But it does mean the routine use of compounded versions is becoming harder to justify under federal rules.

The practical takeaway: if you are getting a GLP-1 medicine from a compounding pharmacy or a telehealth seller, it is worth confirming exactly what product you are receiving and why. The answer can affect safety, legality, and whether your prescription can be filled the way it was before.

What changed

On April 1, FDA reminded compounders that compounded drugs must meet the usual limits for 503A and 503B compounding. The agency said compounded products should not be essentially copies of commercially available drugs unless a prescriber documents a significant patient-specific difference. FDA also said semaglutide and tirzepatide no longer appear on the drug shortage list, which matters because shortage status has been one of the main reasons compounding was allowed for these drugs.

Then on April 30, FDA said it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. That would make it harder for outsourcing facilities to compound these drugs from bulk substances unless a clear legal exception applies. FDA said it did not identify a clinical need for outsourcing facilities to compound these medicines from bulk substances.

What this means for access

FDA’s drug-shortage framework is not all-or-nothing. A drug can be in short supply nationally, temporarily unavailable at a local pharmacy, or fully resolved on the federal shortage list. FDA says it works with manufacturers to reduce shortages and that local supply problems do not always mean a national shortage.

For patients, that means some compounded GLP-1 products may still be available in limited situations, but the margin for routine compounding is narrowing. Access can also vary by state law, prescriber judgment, and the type of pharmacy filling the prescription.

Safety concerns FDA has flagged

FDA says it has received reports of dosing errors with compounded injectable semaglutide, including cases that led to hospitalization. In some cases, people measured or self-administered the wrong dose, and in others a health professional miscalculated the dose. Reported symptoms included nausea, vomiting, diarrhea, abdominal pain, and constipation.

FDA also warned that some compounded semaglutide products may use salt forms such as semaglutide sodium or semaglutide acetate. The agency says those are different active ingredients from the ones used in approved drugs and that it is not aware of a lawful basis for using them in compounding.

FDA has also received adverse-event reports tied to compounded semaglutide and tirzepatide, though the agency notes these reports are likely undercounted because not all compounding pharmacies are required to report them.

What patients should ask

If you are filling a GLP-1 prescription, ask your pharmacist or prescriber:

Is this FDA-approved, or is it compounded?
If it is compounded, what is the exact active ingredient and dose?
Are you using a salt form or a bulk substance?
What does the label say about measuring and dosing?
Will my insurance cover this, or do I need a different pharmacy in my network?

MedlinePlus notes that many health plans require patients to use certain pharmacies, which can affect whether a prescription is covered or filled without delays. If a pharmacy says it cannot fill your prescription, ask whether another in-network pharmacy or a mail-order option is available.

Bottom line

Compounded GLP-1 access may not end all at once, but federal policy is moving in a more restrictive direction as shortages ease. Patients should verify what they are receiving and should not assume a product marketed as a GLP-1 medicine is the same as an FDA-approved version.

If you have severe nausea, vomiting, dehydration, or other concerning symptoms after taking a GLP-1 product, seek medical care promptly.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.